In the past week, SMMT stock has gone down by -4.32%, with a monthly gain of 14.39% and a quarterly plunge of -27.23%. The volatility ratio for the week is 11.72%, and the volatility levels for the last 30 days are 12.65% for Summit Therapeutics Inc. The simple moving average for the past 20 days is -9.50% for SMMT’s stock, with a -20.60% simple moving average for the past 200 days.
Is It Worth Investing in Summit Therapeutics Inc. (NASDAQ: SMMT) Right Now?
and a 36-month beta value of -1.05. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
The average price predicted for Summit Therapeutics Inc. (SMMT) by analysts is $4.00, The public float for SMMT is 114.58M, and at present, short sellers hold a 4.54% of that float. On May 26, 2023, the average trading volume of SMMT was 2.19M shares.
SMMT) stock’s latest price update
The stock of Summit Therapeutics Inc. (NASDAQ: SMMT) has decreased by -9.88 when compared to last closing price of 1.72.Despite this, the company has seen a loss of -4.32% in its stock price over the last five trading days.
SMMT Trading at -6.63% from the 50-Day Moving Average
After a stumble in the market that brought SMMT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.18% of loss for the given period.
Volatility was left at 12.65%, however, over the last 30 days, the volatility rate increased by 11.72%, as shares surge +13.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.49% lower at present.
During the last 5 trading sessions, SMMT fell by -4.32%, which changed the moving average for the period of 200-days by +60.46% in comparison to the 20-day moving average, which settled at $1.7218. In addition, Summit Therapeutics Inc. saw -63.53% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at SMMT starting from Zanganeh Mahkam, who purchase 15,973,743 shares at the price of $1.05 back on Mar 08. After this action, Zanganeh Mahkam now owns 23,395,269 shares of Summit Therapeutics Inc., valued at $16,772,430 using the latest closing price.
Zanganeh Mahkam, the Co-Chief Executive Officer of Summit Therapeutics Inc., purchase 7,553,301 shares at $1.05 during a trade that took place back on Mar 08, which means that Zanganeh Mahkam is holding 9,884,095 shares at $7,930,966 based on the most recent closing price.
Stock Fundamentals for SMMT
Current profitability levels for the company are sitting at:
- -8330.93 for the present operating margin
The net margin for Summit Therapeutics Inc. stands at -6127.56. The total capital return value is set at -89.97, while invested capital returns managed to touch -66.53. Equity return is now at value -92.30, with -33.60 for asset returns.
Based on Summit Therapeutics Inc. (SMMT), the company’s capital structure generated 0.59 points at debt to equity in total, while total debt to capital is 0.58. Total debt to assets is 0.45, with long-term debt to equity ratio resting at 0.09. Finally, the long-term debt to capital ratio is 0.09.
When we switch over and look at the enterprise to sales, we see a ratio of 303.27, with the company’s debt to enterprise value settled at 0.00. The receivables turnover for the company is 0.10 and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.41.
To sum up, Summit Therapeutics Inc. (SMMT) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.